List view / Grid view
Analysts say M&A deals continue to be a core driver…
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
New research has shown that complex collaborations and partnerships are…
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
Research has found that the top five pharmaceutical companies averaged…
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
